A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: Discovery of a potential atypical antipsychotic agent

Journal of Medicinal Chemistry

Volumn 42, Issue 25, 1999, Pages 5181-5187

  Belliotti, Thomas R ^a   Wustrow, David J ^a   Brink, Wouter A ^a   Zoski, Kim T ^a   Shih, Yu Hsin ^a   Whetzel, Steven Z ^a   Georgic, Lynn M ^a   Corbin, Ann E ^a   Akunne, Hyacinth C ^a   Heffner, Thomas G ^a   Pugsley, Thomas A ^a   Wise, Lawrence D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [4 (4 CHLOROPHENYL)PIPERIZIN 1 YL]METHYL] 4H BENZ[1,4]OXAZIN 3 ONE; AMPHETAMINE DERIVATIVE; BENZOXAZINONE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENYL GROUP; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTIPSYCHOTIC AGENTS; CHO CELLS; CORPUS STRIATUM; CRICETINAE; DOPAMINE; DOPAMINE ANTAGONISTS; HIPPOCAMPUS; MAGNETIC RESONANCE SPECTROSCOPY; OXAZINES; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4;

EID: 0033576595     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990277d     Document Type: Article

References (36)

1. Reynolds, G. P. Developments in the Drug Treatment of Schizophrenia. Trends Pharmacol. Sci. 1992, 13, 116-121.
2. Knable, M. B.; Weinberger, D. R. Dopamine, the Prefrontal Cortex and Schizophrenia. J. Psychopharmacol. Oxford 1997, 11, 123-31.
3. Baldessarini, R. J.; Tarsey, D. Dopamine and the Pathophysiology of Dyskinesias Induced by Antipsychotic Drugs. Annu. Rev. Neurosci. 1980, 3, 23.
4. Ben-Jonathon, N. Dopamine: A Prolactin Inhibiting Hormone. Endocr. Rev. 1985, 6, 564.
5. Giros, B.; Martes, M. P.; Sokoloff, P.; Schwratz, J. C. Cloning of the Human Dopaminergic D3 Receptor Gene and its Chromosome Identification. C. R. Acad. Sci. Ser. 3 1990, 311, 501-8.
6. Van Tol, H. H. M.; Bunzow, J. R.; Guan, H. C.; Sunahara, R. K.; Seeman, P.; Niznik, H. B.; Civelli, O. Cloning of the Gene for a Human Dopamine D4 Receptor with High Affinity for the Antipsychotic Clozapine. Nature 1991, 350 (6319), 610-14.
7. Matsumoto, M.; Hidaka, K.; Tada, S.; Tasaki, Y.; Yamaguchi, T. Low levels of mRNA for Dopamine D4 Receptor in Human Cerebral Cortex and Striatum. J. Neurochem. 1996, 66, 915-919.
8. Mrzljak, L.; Bergson, C.; Pappy, M.; Huff, R.; Levenson, R.; Goldamn-Rakic, P. S. Localization of Dopamine D4 Receptors in GABAergic Neurons of the Primate Brain. Nature 1996, 381, 245-246.
9. Rowley, M.; Collins, I.; Broughton, H. B.; Davey, W. B.; Baker, R.; Emms, F.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C. I.; Freedman, S. B.; Ball, R.; Leeson, P. D. 4-Heterocyclylpiperidines as Selective High-Affinity Ligands at the Human Dopamine D4 Receptor. J. Med. Chem. 1997, 40, 2374-2385.
10. Fritton, A.; Heel, R. C. Clozapine. A Review of its Pharmacological Properties and Therapeutic Use in Schizophrenia. Drugs 1990, 40, 722-747.
11. Reynolds, G. P. What is an Atypical Antipsychotic? J. Psychopharmacol. 1997, 11, 195-9.
12. Sanyal, S.; Van Tol, H. H. Review of the Role of Dopamine D4 Receptors in Schizophrenia and antipsychotic Action. J. Psychiatr. Res. 1997, 31, 219-32.
13. Krupp, P.; Barnes, P. Clozapine-Associated Agranularcytoais: Risk and Aetiology. Br. J. Psychiatry. 1992, 160 (Suppl. 17), 38-41.
14. TenBrink, R. E.; Bergh, C. L.; Duncan, J. N.; Harris, D. W.; Huff, R. M.; Lahti, R. A.; Lawson, C. F.; Lutzke, B. S.; Martin, I. J.; et al. (S)-(-)-4-[4-[2-(Isochroman-1-yl)ethyl]piperazin-1-yl]benzene-sulfonamide, a Selective Dopamine D4 Antagonist. J. Med. Chem. 1996, 39, 2435-2437.
15. Thurkauf, A.; Yuan, J.; Chen, X.; He, X. S.; Wasley, J. W. F.; Woodruff, K. H.; Meade, R.; Hoffman, D. C.; Donovan, H.; et al. 2-Phenyl-4(5)-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]imidazole. A Highly Selective Antagonist at Cloned Human D4 Receptors. J. Med. Chem. 1997, 40, 1-3.
16. Bristow, L. J.; Collinson, N.; Cook, G. P.; Curtis, N.; Freedman, S. B.; Kulagowski, J. J.; Leeson, P. D.; Patel, S.; Ragan, C. I.; Ridgill, M.; Saywell, K. L.; Tricklebank, M. D. L-745870, a Subtype Selective Dopamine D4 Receptor Antagonist, Does not Exhibit a Neuroleptic-like Profile in Rodent Behavioral Tests. J. Pharmacol. Exp. Ther. 1997, 283, 1256-1263.
17. Sanner, M. A.; Chappie, T. A.; Dunaiskis, A. R.; Fliri, A. F.; Desai, K. A.; Zorn, S. H.; Jackson, E. R.; Johnson, C. G.; Morrone, J. M.; Seymour, P. A.; Majchrzak, M. J.; Faraci, W. S.; Collins, J. L.; Duignan, D. B.; Di Prete, C. C.; Lee, J. S.; Trozzi, A. Synthesis, SAR, and Pharmacology of CP-293, 019: A Potent, Selective Dopamine D4 Receptor Antagonist. Bioorg. Med. Chem. Lett. 1998, 8, 725-730.
18. Rowley, M.; Broughton, H. B.; Collins, I.; Baker, R.; Emms, F.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C. I.; et al. 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: A Potent, Selective Antagonist at Human Cloned Dopamine D4 Receptors. J. Med. Chem. 1996, 39, 1943-5.
19. Kulagowski, J. J.; Broughton, H. B.; Curtis, N. R.; Mawer, I. M.; Ridgill, M. P.; Baker, R.; Emms, F.; Freedman, S. B.; Marwood, R.; et al. 3-[[4-(4-Chlorophenyl)piperazin-1-yl]methy]]-1H-pyrrolo[2,3-6]pyridine: An Antagonist with High Affinity and Selectivity for the Human Dopamine D4 Receptor. J. Med. Chem. 1996, 39, 1941-2.
20. Boyfield, I.; Coldwell, M. C.; Hadley, M. S.; Healy, M. A. M.; Johns, A.; Nash, D. J.; Riley, G. J.; Scott, E. E.; Smith, S. A.; et al. N-(substituted-phenyl)piperazines: Antagonists with High Binding and Functional Selectivity for Dopamine D4 Receptors. Bioorg. Med. Chem. Lett. 1996, 6, 1227-1232.
21. Boyfield, I.; Brown, T. H.; Coldwell, M. C.; Cooper, D. G.; Hadley, M. S.; Hagan, J. J.; Healy, M. A.; Johns, A.; King, R. J.; et al. Design and Synthesis of 2-Naphthoate Esters as Selective Dopamine D4 Antagonists. J. Med. Chem. 1996, 39, 1946-8.
22. Wright, J. L.; Gregory, T. F.; Heffner, T. G.; Mackenzie, R. G.; Pugsley, T. A.; Vander Meulen, S.; Wise, L. D. Discovery of Selective Dopamine D4 Receptor Antagonists: 1-aryloxy-3-(4-aryloxypiperidinyl)-2-propanols. Bioorg. Med. Chem. Lett. 1997, 7, 1377-1380.
23. Unangst, P. C.; Capiris, T.; Connor, D. T.; Heffner, T. G.; MacKenzie, R. G.; Miller, S. R.; Pugsley, T. A., Wise, L. D. Chromeno[3,4-c]pyridin-5-ones: Selective Human Dopamine D4 Receptor Antagonists as Potential Antipsychotic Agents. J. Med. Chem. 1997, 40, 2688-2693.
24. Unangst, P. C.; Capiris, T.; Connor, D. T.; Doubleday, R.; Heffner, T. G.; MacKenzie, R. G.; Miller, S. R.; Pugsley, T. A.; Wise, L. D. (Aryloxy)alkylamines as Selective Human Dopamine D4 Receptor Antagonists: Potential Antipsychotic Agents. J. Med. Chem. 1997, 40, 4026-4029.
25. Schlachter, S. K.; Poel, T. J.; Lawson, C. F.; Dinh, D. M.; Lajiness, M. E.; Romero, A. G.; Rees, S. A.; Duncan, J. N.; Smith, M. W. Substituted 4-aminopiperidines Having High in vitro Affinity and Selectivity for the Cloned Human Dopamine D4 Receptor. Eur. J. Pharmacol. 1997, 322, 283-286.
26. Belliotti, T. R.; Brink, W. A.; Kesten, S. R.; Rubin, J. R.; Wustrow, D. J.; Zoski, K. T.; Whetzel, S. Z.; Corbin, A. E.; Pugsley, T. A.; Heffner, T. G.; Wise, L. D. Isoindolinone Enantiomers Having Affinity for the Dopamine D4 Receptor. Bioorg. Med. Chem. Lett. 1998, 8, 1499-1502.
27. Kramer, M. S.; Last, B.; Getson, A.; Reines, S. A. The Effects of a Selective D4 Dopamine Receptor Antagonist (L-745,870) in Acutely Psychotic Inpatients with Schizophrenia. Arch. Gen. Psychiatry 1997, 54, 567-572.
28. Gazi, L.; Bobrinac, I.; Danzeisen, M.; Schulpbach, E.; Bruinvels, A. T.; Geisse, S.; Sommer, B.; Hoyer, D.; Tricklebank, M.; Schoeffter, P. The Agonist Activities of the Putative Antipsychotic Agents, L-745,870 and U-101958 in HEK293 Cells Expressing the Human Dopamine D4.4 receptor. Br. J. Pharmacol. 1998, 124, 889-896.
29. Belliotti, T. R.; Kesten, S. R.; Rubin, J. R.; Wustrow, D. J.; Georgie, L. M.; Zoski, K. T.; Akunne, H. C.; Wise, L. D. Novel Cyclohexyl Amides as Potent and Selective D3 Dopamine Receptor Ligands. Bioorg. Med. Chem. Lett. 1997, 7, 2403-2408.
30. Pugsley, T. A.; Davis, M. D.; Akunne, H. C.; Mackenzie, R. G.; Shih, Y. H.; Damsma, G.; Wikstrom, H.; Whetzel, S. Z.; Georgic, L. M.; Cooke, L. W.; Demattos, S. B.; Corbin, A. E.; Glase, S. A.; Wise, L. D. Neurochemical and Functional Characterization of the Preferentially Selective Dopamine D3 Agonist PD 128907. J. Pharmacol. Exp. Ther. 1995, 275, 1355-1366.
31. Arnt, J. Differential Effects of Classical and Newer Antipsychotics on the Hypermotility Induced by Two Dose Levels of d-Amphetamine. Eur. J. Pharmacol. 1995, 283, 55-62.
32. Braff, D. L.; Stone, C.; Callaway, E.; Geyer, M.; Glick, I.; Bali, L. Prestimulus Effects on Human Startle Reflex in Normal Patients and Schizophrenics. Psychophysiology 1978, 339-343.
33. Mansbach, R. S.; Geyer, M. A.; Braff, D. L. Dopaminergic Stimulation Disrupts Sensorimotor Gating in the Rat. Psychopharmacology 1988, 229-308.
34. Ellenbroek, B. A.; Peeters, B. W.; Honig, W. M.; Cools, A. R. The Paw Test: A Behavioral Paradigm for Differentiating between Classical and Atypical Neuroleptic Drugs. Psychopharmacology 1987, 93, 343-348.
35. Guzman, A.; Romero, M. Vilsmeier-Haack Reaction with Glutarimides. Synthesis of 2,6-Dichloro-l,4-dihydropyridine-3,5-dicarboxaldehydes. J. Org. Chem. 1990, 22, 5793-5797.
36. Whetzel, S. Z.; Shih, Y. H.; Georgic, L. M.; Akunne, H. C.; Pugsley, T. A. Effects of the Dopamine D3 Antagonist PD 58491 and its Interaction with the Dopamine D3 Agonist PD 128907 on Brain Dopamine Synthesis in Rat. J. Neurochem. 1997, 6.9, 2363-2368.